FDA Rejects Ocular Therapeutix Eye Drug
The U.S. Food and Drug Administration on Tuesday rejected Ocular Therapeutix Inc.'s eye disease drug Dextenza, citing problems with manufacturing and quality control testing uncovered during a May inspection of the...To view the full article, register now.
Already a subscriber? Click here to view full article